Dear Dixie,
Thank you for contacting me to express your support for increasing funding for ovarian cancer research.
According
to the American Cancer Society, there will be 22,000 new cases of
ovarian cancer in 2013 and 14,400 deaths nationwide. One out of 72
women will develop ovarian cancer in her lifetime, and the disease is
the fifth leading cause of cancer deaths among women in the U.S.
Ovarian cancer is also difficult to diagnose, and there are no
screenings for the disease.
For
these reasons, I signed on to Senator Stabenow's resolution to declare
September National Ovarian Cancer Awareness Month. It is important that
we alert women and physicians to the symptoms of this disease so that
it can be diagnosed and treated as early as possible. Additionally, I
strongly support increasing our government's investment in scientific
research to build the knowledge base necessary to advance medicine. I
am proud to have supported increased funding during the appropriations
process for the National Institutes of Health (NIH), our nation's
premier medical research agency and funder of academic medical research
around the country. Robust funding for the NIH gives scientists and
physicians the support they need to carry out research that will change
the landscape of diagnosis and treatment of ovarian cancer. During the
appropriations process, I was also proud to support $20 million in
funding for the Ovarian Cancer Research Program at the Department of
Defense.
We need
to support patients, families, and providers to ensure better outcomes
for Americans suffering from this disease, and I will continue to fight
alongside my Senate colleagues to find ways to provide funding that will
lead to a better screenings for ovarian cancer, as well as better
treatments and a cure.
Thank
you again for contacting me about this issue, and please do not hesitate
to reach out to my office again in the future about issues of
importance to you or if I can be of assistance.
Sincerely,
Elizabeth Warren
United States Senator
United States Senator
No comments:
Post a Comment